A Medical Device Daily

Abbott (Abbott Park, Illinois) reported the initiation of SPIRIT PRIME, a clinical trial to study the performance of the company's Xience Prime everolimus-eluting coronary stent system, currently an investigational device, for the treatment of coronary artery disease.

Xience Prime uses the same biocompatible polymer as the Xience V stent system. The Xience Prime uses cobalt chromium technology, which allows for very thin struts while maintaining strength to support the vessel as well as good visibility under X-ray during the stent implantation procedure.

"Based upon the market-leading technology of Xience V, Xience Prime will be available in a greater breadth of sizes, and is designed to provide improved deliverability," said Charles Simonton, MD, divisional VP, medical affairs, and chief medical officer, Abbott Vascular.